Autopsy report · NCT03828136

Novum Vitrium® Cervical Cage in Anterior Cervical Discectomy and Fusion

“Sponsor business decision”

The sponsor’s own words in the registry.

Life of this trial

• Registered 3 months before it started.
• Ran for about 2 years 11 months before it stopped.
• 25 participants enrolled.
• No results are posted on the registry.

Vital statistics

Status

Terminated

Phase

Na

Sponsor

Bio2 Technologies

Sponsor type

Industry

Conditions

Symptomatic Cervical Disc Disease

Interventions

Novum Vitrium® Cervical Interbody Device; Allograft Ring or Block

Participants

25

Sites

7

Countries

United States

Trials that died the same way

• Study of Vitespen (HSPPC-96, Oncophage ®) for Immune Response Assessment in Participants With Resectable Renal Cell Carcinoma at Intermediate Risk of Recurrence
  “Sponsor's business decision” (97% match in meaning)
• Study With Bispecific Antibody Engaging T-cells, in Patients With Progressive Cancer Diseases With Positive PSCA Marker
  “business decision by sponsor” (97% match in meaning)
• Efficacy and Safety of Using MPC-5971 in Subjects Undergoing Shock Wave Lithotripsy
  “Sponsor Corporate Business Decision” (91% match in meaning)
• A Phase 1a/1b Study of ACTM-838 in Patients With Advanced Solid Tumors
  “Sponsor's strategic business decision” (90% match in meaning)
• Nab-Paclitaxel/STI-3031 Complex (AP160-Complex) for the Treatment of Advanced or Metastatic Solid Tumors
  “Sponsor business considerations” (90% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.